EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter, randomized, open-label study of the safety and efficacy of histamine dihydrochloride and interferon alpha-2b for the treatment of chronic hepatitis C 48-Week results



Multicenter, randomized, open-label study of the safety and efficacy of histamine dihydrochloride and interferon alpha-2b for the treatment of chronic hepatitis C 48-Week results



Journal of Hepatology 34(Supplement 1): 165-166, April




(PDF same-day service: $19.90)

Accession: 035349992

Download citation: RISBibTeXText

DOI: 10.1016/s0168-8278(01)81481-1



Related references

A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C. Journal of Viral Hepatitis 9(5): 346-353, 2002

A multicenter, randomized, open-label study of the safety and effectiveness of pegylated interferon alpha 2b and interferon alpha 2b in treating HBeAg positive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 14(5): 323-326, 2006

Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma. Annals of Oncology 18(10): 1691-1697, 2007

Triple combination therapy with histamine dihydrochloride, interferon alpha-2b and ribavirin for chronic hepatitis C treatment-failures 48 Week results. Hepatology 34(4 Pt 2): 332A, October, 2001

A phase II study of the combination of histamine dihydrochloride and interferon alpha-2b as initial therapy in chronic hepatitis C patients 48-Week results. Gastroenterology 120(5 Supplement 1): A 381-A 382, April, 2001

Alpha interferon therapy in Danish haemophiliac patients with chronic hepatitis C: results of a randomized controlled open label study comparing two different maintenance regimens following standard interferon-alpha-2b treatment. Haemophilia 4(1): 25-32, 1999

Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 33(1): 25-29, 2005

Multicenter, randomized, open-label study of the safety and efficacy of interferon alfa-2b plus ribavirin for the treatment of HCV infection in HIV-infected persons. Hepatology 32(4 Pt 2): 558A, October, 2000

Efficacy and safety of the combination of histamine dihydrochloride and interferon alpha-2b in a phase II trial in naive patients with chronic hepatitis C. Hepatology 34(4 Pt 2): 350A, October, 2001

A phase II dose-ranging study of histamine dihydrochloride and interferon-alpha-2b as a new therapy for chronic hepatitis C 12-week interim analysis. Journal of Hepatology 32(Supplement 2): 104, 2000

Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations. Current Medical Research and Opinion 31(7): 1413-1429, 2016

Treatment with pegylated-interferon alpha-2b +ribavirin in relapsers to standard interferon+ribavirin in chronic hepatitis C Efficacy and safety results from a randomized multicentric French study. Hepatology 36(4 Part 2): 359A, October, 2002

Daily versus three times weekly interferon alpha-2b plus ribavirin for the treatment of hepatitis C infection in HIV-infected persons A multicenter, randomized, open-label study. Hepatology 36(4 Part 2): 582A, October, 2002

Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial. Hepatology 25(2): 445-448, 1997

A multi-center, randomized, open-label study of the safety and efficacy of interferon alpha-2b plus ribavirin for the treatment of HCV infection in HIV-infected persons. Hepatology 34(4 Pt 2): 594A, October, 2001